NRx Pharmaceuticals (NRXP) Competitors $2.63 -0.15 (-5.40%) Closing price 04:00 PM EasternExtended Trading$2.57 -0.06 (-2.28%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRXP vs. LFVN, IVA, HURA, SLS, CYBN, ACOG, FDMT, MOLN, RNAZ, and DERMShould you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include LifeVantage (LFVN), Inventiva (IVA), TuHURA Biosciences (HURA), SELLAS Life Sciences Group (SLS), Cybin (CYBN), Alpha Cognition (ACOG), 4D Molecular Therapeutics (FDMT), Molecular Partners (MOLN), TransCode Therapeutics (RNAZ), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry. NRx Pharmaceuticals vs. LifeVantage Inventiva TuHURA Biosciences SELLAS Life Sciences Group Cybin Alpha Cognition 4D Molecular Therapeutics Molecular Partners TransCode Therapeutics Journey Medical LifeVantage (NASDAQ:LFVN) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, valuation, profitability, dividends, risk, media sentiment and institutional ownership. Which has more volatility and risk, LFVN or NRXP? LifeVantage has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Do analysts recommend LFVN or NRXP? LifeVantage currently has a consensus price target of $30.50, indicating a potential upside of 139.78%. NRx Pharmaceuticals has a consensus price target of $28.50, indicating a potential upside of 944.34%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than LifeVantage.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LifeVantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00NRx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Do insiders and institutionals have more ownership in LFVN or NRXP? 35.3% of LifeVantage shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 20.7% of LifeVantage shares are held by company insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer LFVN or NRXP? In the previous week, NRx Pharmaceuticals had 8 more articles in the media than LifeVantage. MarketBeat recorded 9 mentions for NRx Pharmaceuticals and 1 mentions for LifeVantage. LifeVantage's average media sentiment score of 1.25 beat NRx Pharmaceuticals' score of 0.61 indicating that LifeVantage is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeVantage 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is LFVN or NRXP more profitable? LifeVantage has a net margin of 3.46% compared to NRx Pharmaceuticals' net margin of 0.00%. LifeVantage's return on equity of 34.29% beat NRx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets LifeVantage3.46% 34.29% 15.04% NRx Pharmaceuticals N/A N/A -449.16% Which has stronger earnings & valuation, LFVN or NRXP? LifeVantage has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifeVantage$222.35M0.72$2.94M$0.6918.43NRx PharmaceuticalsN/AN/A-$30.15M-$2.01-1.36 Does the MarketBeat Community believe in LFVN or NRXP? LifeVantage received 198 more outperform votes than NRx Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave NRx Pharmaceuticals an outperform vote while only 77.97% of users gave LifeVantage an outperform vote. CompanyUnderperformOutperformLifeVantageOutperform Votes22377.97% Underperform Votes6322.03% NRx PharmaceuticalsOutperform Votes25100.00% Underperform VotesNo Votes SummaryLifeVantage beats NRx Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get NRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXP vs. The Competition Export to ExcelMetricNRx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.80M$6.55B$5.40B$8.53BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-1.309.1626.7419.97Price / SalesN/A258.53394.93122.22Price / CashN/A65.8538.2534.62Price / Book-2.016.546.874.59Net Income-$30.15M$143.98M$3.23B$248.18M7 Day Performance22.25%4.65%5.01%2.15%1 Month Performance48.40%9.18%12.82%16.14%1 Year Performance-28.11%-1.33%17.63%8.06% NRx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXPNRx Pharmaceuticals1.9528 of 5 stars$2.63-5.4%$28.50+983.7%-31.5%$45.30MN/A-1.232News CoverageEarnings ReportGap UpHigh Trading VolumeLFVNLifeVantage3.9893 of 5 stars$13.18-1.6%$30.50+131.4%+84.5%$165.91M$222.35M23.54260Positive NewsHigh Trading VolumeIVAInventiva1.5119 of 5 stars$3.15+1.3%$10.40+230.2%-17.1%$165.30M$9.20M0.00100Gap DownHURATuHURA BiosciencesN/A$3.77-3.8%$12.67+236.0%N/A$164.67MN/A0.00N/ANews CoverageEarnings ReportAnalyst RevisionSLSSELLAS Life Sciences Group0.451 of 5 stars$1.75+7.4%N/A+31.1%$162.64M$1M-2.5410Gap UpHigh Trading VolumeCYBNCybin2.7493 of 5 stars$7.50+11.6%$86.00+1,046.7%N/A$161.08MN/A-1.7150News CoverageHigh Trading VolumeACOGAlpha Cognition1.6757 of 5 stars$10.00+15.6%$20.00+100.0%N/A$160.20MN/A-3.91N/AEarnings ReportHigh Trading VolumeFDMT4D Molecular Therapeutics2.9487 of 5 stars$3.80+10.5%$29.56+677.8%-85.2%$159.36M$23,000.00-1.33120Gap UpMOLNMolecular Partners1.977 of 5 stars$3.93+2.4%$12.00+205.0%+5.6%$158.84M$4.97M-1.83180News CoverageEarnings ReportAnalyst RevisionGap UpRNAZTransCode Therapeutics2.4231 of 5 stars$6.70-17.9%$280.00+4,079.1%-100.0%$156.39MN/A0.009Positive NewsEarnings ReportHigh Trading VolumeDERMJourney Medical2.1173 of 5 stars$6.75-2.6%$9.88+46.3%+102.4%$155.95M$56.13M-7.1890News CoverageEarnings ReportAnalyst Revision Related Companies and Tools Related Companies LifeVantage Alternatives Inventiva Alternatives TuHURA Biosciences Alternatives SELLAS Life Sciences Group Alternatives Cybin Alternatives Alpha Cognition Alternatives 4D Molecular Therapeutics Alternatives Molecular Partners Alternatives TransCode Therapeutics Alternatives Journey Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRXP) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NRXP Stock Free NRXP Stock Alerts